Table 3 Association of cytoplasmic HuR expression with COX-2 expression and selected clinicopathological factors in patients with colorectal adenocarcinoma
Characteristic | All cases | HuR cytoplasmic negative | HuR cytoplasmic positive | Significance |
|---|---|---|---|---|
All carcinomas | 87 (100%) | 41 (47.1%) | 46 (52.9%) | |
COX-2 expression | 0.015a | |||
Negative | 34 (100%) | 22 (64.7%) | 12 (35.3%) | |
Positive | 53 (100%) | 19 (35.8%) | 34 (64.2%) | |
Histological type | 0.041a | |||
Adenocarcinoma | 77 (100%) | 33 (42.9%) | 44 (57.1%) | |
Mucinous adenocarcinoma | 10 (100%) | 8 (80.0%) | 2 (20.0%) | |
DUKES stage | 0.028b | |||
A | 21 (100%) | 13 (61.9%) | 8 (38.1%) | |
B | 30 (100%) | 15 (50.0%) | 15 (50.0%) | |
C | 29 (100%) | 12 (41.4%) | 17 (58.6%) | |
D | 7 (100%) | 1 (14.3 %) | 6 (85.7 %) | |
AJCC stage | 0.039b | |||
I | 23 (100%) | 14 (60.9%) | 9 (39.1%) | |
II | 29 (100%) | 14 (48.3%) | 15 (51.7%) | |
III | 28 (100%) | 12 (42.9%) | 16 (57.1%) | |
IV | 7 (100%) | 1 (14.3%) | 6 (85.7%) | |
Histological grade | NSb | |||
G1 | 5 (100%) | 3 (60.0%) | 2 (40.0%) | |
G2 | 67 (100%) | 31 (46.3%) | 36 (53.7%) | |
G3 | 15 (100%) | 7 (46.7%) | 8 (53.3%) |
